ArticleScientific reports2026
Stepwise effects of formulation additives and process parameters on ethanol injection-prepared nanoliposomes for cancer delivery: a preformulation study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ethanol injection method has emerged as a simple and rapid technique for the preparation of nanoliposomes. Since the size and polydispersity of nanoliposomes are crucial properties which directly affect their therapeutic effectiveness, the focus of this paper was to study the influence of different additives such as cholesterol, poloxamer 188, PEG 400, and cationic lipids, as well as process parameters on the particle size and polydispersity index (PDI) of nanoliposomes intended for cancer treatment. The optimum conditions were using phospholipid concentration 20 mg/mL in ethanol, injection of the ethanolic phase along the direction of aqueous phase, use of hand-press injection of the ethanolic solution, and the use of buffer as aqueous phase. The nanoliposomes had an average size of 91.12 ± 5.50 nm with a PDI of 0.15 ± 0.01. Their properties were influenced by cholesterol content and additives such as poloxamer 188, PEG 400, and cationic lipids. PEG 400 reduced particle size to 79.70 ± 1.80 nm, while cholesterol and cationic lipids increased it to 126.29 ± 8.39 nm and 130.34 ± 8.77 nm, respectively. The optimized formulation co-loaded with apigenin and gallic acid showed high entrapment efficiency (84.74 ± 2.33% and 60.06 ± 3.94%, respectively). It also demonstrated significantly higher cytotoxicity than free drugs, with a much lower IC50 (2.99 ± 0.2 µM vs. 25.97 ± 0.9 µM), highlighting the importance of formulation parameters. This suggests that preformulation studies are crucial to delineate the best process parameters and optimum additives and their concentrations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.